Stock EQ EQUILLIUM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Equillium, Inc.

Equities

EQ

US29446K1060

Delayed Nasdaq
Other stock markets
 03:02:50 2024-05-20 pm EDT 		5-day change 1st Jan Change
1.53 USD -1.92% Intraday chart for Equillium, Inc. -0.65% +111.62%
May. 14 Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease CI
May. 09 Earnings Flash (EQ) EQUILLIUM Reports Q1 Revenue $10.7M MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
H.C. Wainwright Adjusts Price Target on Equillium to $5 From $4, Keeps Buy Rating
MT
HC Wainwright Adjusts Price Target on Equillium to $4 From $4.50, Keeps Buy Rating
MT
HC Wainwright Adjusts Equillium's Price Target to $4.50 From $5.50, Maintains Buy Rating
MT
Stifel Adjusts Price Target on Equillium to $7 From $12, Maintains Buy Rating
MT
SVB Securities Lowers Equillium's Price Target to $7 From $12, Maintains Outperform Rating
MT
Cantor Fitzgerald Adjusts Price Target for Equillium to $4 From $14, Maintains Overweight Rating
MT
HC Wainwright Adjusts Equillium's Price Target to $20 from $15, Maintains Buy Rating
MT
HC Wainwright Adjusts Equillium's Price Target to $15 From $12, Reiterates Buy Rating
MT
SVB Leerink Adjusts Equillium Price Target to $14 From $18, Outperform Rating Kept
MT
EQUILLIUM : Cantor Fitzgerald Starts Equillium at Outperform with $14 Price Target
MT
EQUILLIUM : JonesTrading Starts Equillium at Buy With $14 Price Target
MT
EQUILLIUM : HC Wainwright Adjusts Equillium's Price Target to $12 from $22, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EQ Stock
  4. News Equillium, Inc.
  5. Analyst Reco.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW